Takeda Pharmaceutical Company Limited

4502

JP3463000004

Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas: - sale of drugs and consumer care products; - services. Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).

Sector

Pharmaceuticals

Calendar

04/06/2024 - Sleep Meeting

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Takeda Pharmaceutical Company Limited

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

4,130 JPY

Average target price

4,762 JPY

Spread / Average Target

+15.31%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TAKEDA PHARMACEUTICAL COMPANY LIMITED	+1.87%	41.69B
ELI LILLY AND COMPANY	+32.09%	693B
NOVO NORDISK A/S	+29.39%	584B
JOHNSON & JOHNSON	-1.34%	372B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+7.39%	294B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	211B
NOVARTIS AG	+10.02%	210B
AMGEN INC.	+8.49%	168B

Other Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 11:30:00 17/05/2024 am IST			5-day change	1st Jan Change
4,130 ^JPY	-0.19%		+0.02%	+1.87%

16/05	Takeda Canada Completes LOI Stage for Post-Transplant Cytomegalovirus Treatment	MT
15/05	Takeda Pharmaceutical's Dengue Vaccine Granted WHO Prequalification	MT

Takeda Canada Completes LOI Stage for Post-Transplant Cytomegalovirus Treatment	16/05	MT
Takeda Pharmaceutical's Dengue Vaccine Granted WHO Prequalification	15/05	MT
FDA extends review of Ascendis Pharma's hormone disorder therapy	15/05	RE
Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute	14/05	MT
Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute	14/05	MT
Sector Update: Health Care Stocks Mixed Late Afternoon	14/05	MT
Sector Update: Health Care	14/05	MT
Top Midday Gainers	14/05	MT
AC Immune Enters Licensing Deal for Alzheimer's Disease Drug Candidate	13/05	MT
Takeda Pharmaceutical, AC Immune Agree to Option and Licence Agreement, Including on Alzheimer's Treatment Candidate	13/05	MT
AC Immunity Shares Soar on Exclusive License Deal with Takeda	13/05	DJ
Takeda Pharmaceutical's Attributable Profit Falls 55% in Fiscal 2024	10/05	MT
Health Care Climbs as Obesity-Drug Optimism Returns - Health Care Roundup	10/05	DJ
Sector Update: Health Care Stocks Steady Pre-Bell Thursday	09/05	MT
Transcript : Takeda Pharmaceutical Company Limited, 2024 Earnings Call, May 09, 2024	09/05
Takeda Pharmaceutical's Fiscal Q1 Core Earnings Decline, Revenue Increases; Fiscal 2024 Outlook Issued	09/05	MT
Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss -- Update	09/05	DJ
Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss	09/05	DJ
Japan's Takeda Pharma says full-year profit slumps 56%	09/05	RE
Takeda Pharmaceutical Company Limited Announces Demise of its Board Member, Olivier Bohuon	09/05	CI
Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Full Year of 2024	09/05	CI
Takeda Pharmaceutical Company Limited Declares Dividend for the Year Ended March 31, 2024, Payable June 27, 2024; Provides Dividend Guidance for the Second Quarter-End and Year-End of Fiscal Year Ending March 31, 2025	09/05	CI
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion	30/04	RE
EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug	26/04	MT
Hutchmed notes CHMP's positive opinion for fruiquintinib approval	26/04	AN